PicoCELA (NASDAQ:PCLA) Rating Increased to Hold at Wall Street Zen

PicoCELA (NASDAQ:PCLA) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings raised shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

PicoCELA Trading Up 4.2%

Shares of NASDAQ PCLA opened at $5.41 on Friday. PicoCELA has a one year low of $1.35 and a one year high of $19.50. The firm’s 50 day simple moving average is $5.51 and its two-hundred day simple moving average is $4.44.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. XTX Topco Ltd bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent quarter.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.